Jeffrey Lee Wolf

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

The paper develops a non-viral method using hybrid ssDNA repair templates to improve genome engineering in primary human cells, achieving high knock-in efficiency and cell yields for disease modeling and cell therapy.

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.